How to Improve Adjuvant Therapy in HER2-Positive Breast Cancer

In this video, Ruth M. O’Regan, MD, of the University of Wisconsin, reviews various trials that aimed to improve outcomes or minimize toxicities among patients receiving adjuvant treatment for HER2-positive breast cancer.

O’Regan gave a presentation on this topic during an education session at the 2017 San Antonio Breast Cancer Symposium (SABCS).